Provision Language
RECITALS
WHEREAS, Gilead wishes to facilitate access to its proprietary compound Lenacapavir in 120 (one hundred twenty) countries, as identified in this Agreement, via certain non-exclusive licenses to Licensee with respect to the manufacture and sale of Product (defined below) incorporating Lenacapavir; and
WHEREAS, Licensee wishes to obtain such non-exclusive licenses to facilitate access to Product (defined below) incorporating Lenacapavir for individuals who would benefit medically from pre-exposure prophylaxis and treatment for heavily treatment-experienced patients in such countries, all as more fully described in this Agreement below.